In LNCaP Cells Inhibition of BCL-2 by Antisense Oligonucleonucleotides Results in Compensatory Changes in Apoptosis
Journal: Scientific Journal of Genetics and Gene Therapy (Vol.1, No. 1)Publication Date: 2015-12-30
Authors : Marvin Rubenstein Courtney M.P. Hollowell; Patrick Guinan;
Page : 001-006
Keywords : Antisense oligonucleotides; Prostate cancer; BCL-2; bax; caspase-3; clusterin; AKT-1; Therapy;
Abstract
Antisense oligonucleotides (oligos) have been evaluated for treating prostate cancer in both in vivo and in vitro models. Although most oligos contain a single mRNA binding site, our laboratory evaluates bi-specific oligos directed towards two proteins. This study evaluates the growth inhibition in vitro of the LNCaP cell line employing mono- and bispecific oligos directed against BCL-2 [the second binding site was directed against the epidermal growth factor receptor (EGFR)]. These oligos were administered with lipofectin as part of a nanoparticle delivery system. Additionally, g, the expression of five apoptosis regulatory proteins, BCL-2, bax, caspase-3, clusterin and AKT-1 was evaluated by RTPCR.
Other Latest Articles
- Transposable Elements in Fungi: A Genomic Approach
- A Great Discovery Allergy and Asthma are fully Genetic in Children
- Role of Inhalant and Food Allergens in Child Sensitization: A Prospective Study in 176 Children
- No Association of the Complexin-3 Gene Polymorphism with Schizophrenia
- Heredo-Familial and Pediatric GISTs: Spot the Differences
Last modified: 2019-04-25 21:39:04